## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.42 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($212.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.**
- Source: The Globe and Mail | 20251207T041139 | Bullish | Relevance: 100%
-  The pharmaceutical sector is experiencing a surge, with the iShares U.S. Pharmaceuticals ETF up almost 29% year to date. AbbVie (NYSE: ABBV) is highlighted as a stock to watch, having exceeded Wall Street's expectations with its third-quarter results. The company's top drugs, Skyrizi, Rinvoq, and Humira, have shown significant sales growth, and management projects continued strong performance for Rinvoq and Skyrizi.

**2. Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251208T114452 | Bullish | Relevance: 100%
-  Jump Financial LLC has acquired a new stake in AbbVie Inc. (NYSE:ABBV) by purchasing 84,789 shares valued at approximately $15,739,000 during the second quarter. Other institutional investors also increased their holdings in AbbVie, which reported strong quarterly earnings and increased its dividend. The company also received several positive analyst ratings and price target increases.

**3. California Public Employees Retirement System Sells 778,732 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251207T090752 | Somewhat-Bullish | Relevance: 100%
- The California Public Employees Retirement System (CalPERS) significantly reduced its stake in AbbVie Inc. (NYSE:ABBV) by 13.7%, selling 778,732 shares in Q2 and now holding 4,890,752 shares valued at approximately $907.8 million. This makes AbbVie its 24th largest position, accounting for 0.28% of the fund's holdings. The article also highlights AbbVie's strong Q3 earnings beat, increased quarterly dividend, and a consensus "Moderate Buy" rating from analysts.

**4. iSAM Funds UK Ltd Takes $3.39 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T140740 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd has initiated a new position in AbbVie Inc. (NYSE:ABBV), purchasing 18,267 shares valued at approximately $3.39 million. This investment accounts for 0.7% of the fund's portfolio, making AbbVie its 16th largest holding. AbbVie recently raised its quarterly dividend to $1.73 and reported robust Q3 earnings, surpassing analyst expectations with $1.86 EPS on $15.78 billion in revenue.

**5. Investment Management Corp of Ontario Has $19.88 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T141736 | Bullish | Relevance: 99%
-  Investment Management Corp of Ontario significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 64.4% in the second quarter, bringing its total holdings to $19.88 million. This move is part of a broader trend of institutional investors adjusting their positions in AbbVie, which recently reported strong quarterly earnings and an increased dividend. Analysts maintain a "Moderate Buy" rating for the stock, with a consensus target price of $241.85.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.1B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -0.9% to -4.9% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.89), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.89% (CS: 18) | Weak |
| RSI_14 | 44.1 | Neutral |
| MACD Histogram | -0.89 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $222.99
- **Stop Loss:** $212.71 (4.6% risk)
- **Target:** $243.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $6,466.71
- **Portfolio %:** 6.47%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*